Hepatitis C Research

Pegasys (peginterferon alfa 2-a) plus Ribavirin
•	HCV Quasispecies Association with Early Treatment Response in Singly and Coinfected Patients with Inherited Bleeding - 05/21/04
•	The Effectiveness of Peginterferon and Ribavirin Combination Therapy for Chronic HCV in an Urban Clinic Setting Compared to Pivotal Clinical Trials - 05/21/04
•	Steroid-Free Immunosuppression for Liver Transplantation Recipients with Hepatitis C - 05/21/04
	Treatment with Pegasys of Non Responders to PEG-Intron: Preliminary 24-week Results - 05/19/04
•	Treatment of Chronic Hepatitis C with Pegasys Plus Ribavirin in Hemophiliac Patients Shows High Rate of Sustained Virologic Response - 05/19/04
•	Therapy with Peginterferon Alfa Does Not Increase the Risk of Acute Rejection Post Liver Transplantation 05/17/04

PEG-Intron (peginterferon alfa-2b) plus Ribavirin
•	Treatment with Peginterferon Alfa-2b (PEG-Intron) Plus Ribavirin Is Cost-effective for Hepatitis C Patients with F1 Fibrosis - 05/21/04
•	Weight-based PEG-Intron Plus Ribavirin Is Cost-effective for HIV-HCV Coinfected patients with F2 fibrosis and CD4 >200, but Especially for Those with CD4 >350 - 05/21/04
•	Treatment with PEG-Intron + Ribavirin Is Effective for Patients with Chronic Hepatitis C and Normal Liver Enzymes - 05/19/04
•	Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04
•	Trend to Improved SVR among African-Americans Receiving High Dose Induction Therapy with Conventional Interferon + Ribavirin - 05/19/04
•	Treatment with Pegasys of Non Responders to PEG-Intron: Preliminary 24-week Results - 05/19/04
•	Therapy with Peginterferon Alfa Does Not Increase the Risk of Acute Rejection Post Liver Transplantation 05/17/04

Conventional (non-pegylated) Interferon +/- Ribavirin Therapy
•	Intron A and Ribavirin for the Treatment Of HCV Patients Who Failed Prior Therapy - 05/19/04
•	Trend to Improved SVR among African-Americans Receiving High Dose Induction Therapy with Conventional Interferon + Ribavirin - 05/19/04
•	PEG-Intron Plus Ribavirin for Retreatment of Chronic Hepatitis C 05/17/04

Infergen (consensus interferon) plus Ribavirin
•	High Dose Consensus Interferon Induction Therapy Results in Successful Retreatment of Peginterferon Nonresponder HCV Patients 05/17/04
•	Interim Results of a Pilot Study of the Combination of Consensus Interferon and Interferon Gamma in HCV Nonresponders to Peginterferon Alfa 2 Plus Ribavirin 05/17/04
•	End of Treatment Response for PEG-IFN + Weight-Based Ribavirin Nonresponders Retreated with Consensus Interferon Plus Ribavirin 05/17/04

Cognitive behavioral therapy
•	Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04

Ribavirin Issues
•	Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV Patients Receiving Interferon/Ribavirin Therapy - 05/24/04
•	Factors That Improve the Efficacy of Epoetin Alfa for Maintenance of Ribavirin Weight-Based Dosing - 05/19/04
•	End of Treatment Response for PEG-IFN + Weight-Based Ribavirin Nonresponders Retreated with Consensus Interferon Plus Ribavirin 05/17/04
•	Improved Efficacy and Tolerability in Treating Post-Transplant HCV Utilizing an Escalating Regimen of Pegasys and Ribavirin with Hematopoietic Growth Factors 05/17/04
•	Darbepoetin Alfa improves Ribavirin-related Anemia and Allows for Maintenance of Optimal Ribavirin Dose 05/17/04

Viral eradication
•	In a US Cohort the Large Majority of Individuals with Acute Hepatitis C Experience Spontaneous or Therapy-induced Viral Clearance - 05/19/04

Adherence
•	Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04

Quality of life (QoL)
•	Persistence of Improved Adherence and Quality of Life with Cognitive Behavioral Therapy in Patients Receiving PEG-Intron Plus Ribavirin - 05/19/04

Experimental Therapies and Regimens
•	Dose Escalation Trial Assesses Tolerance, Pharmacokinetics, and Antiviral Activity of NM 283, a Novel Antiviral Treatment for Hepatitis C - 05/24/04
•	Oral IDN 6556, an Anti-Apoptotic Caspase Inhibitor, Lowers Aminotransferases in HCV Patients - 05/24/04
•	Outcome Study on Hepatitis C Therapy with Mistletoe Extract and Solanum Lycopersicum in Nonresponders to Interferon/Ribavirin - 05/24/04
•	Viscum Album in the Therapy of Primary Inoperable Hepatocellular Carcinoma - 05/24/04
•	Viscum Album and Solanum Lycopersicum Inhibit Fibrosis in Chronic Hepatitis C - 05/24/04
•	High Dose Consensus Interferon Induction Therapy Results in Successful Retreatment of Peginterferon Nonresponder HCV Patients 05/17/04
•	Interim Results of a Pilot Study of the Combination of Consensus Interferon and Interferon Gamma in HCV Nonresponders to Peginterferon Alfa 2 Plus Ribavirin 05/17/04
•	Switching from PEG-Intron to an Escalating Pegasys Regimen for Recurrent Hepatitis C Post Liver Transplantation May Improve Virological Response and Tolerability 05/17/04
•	Improved Efficacy and Tolerability in Treating Post-Transplant HCV Utilizing an Escalating Regimen of Pegasys and Ribavirin with Hematopoietic Growth Factors 05/17/04
•	Twice a Week Administration of PEG-Intron Plus Ribavirin in Obtaining SVR Among Patients with HCV Genotype 1 05/17/04

Nonresponders / Relapsers
•	Outcome Study on Hepatitis C Therapy with Mistletoe Extract and Solanum Lycopersicum in Nonresponders to Interferon/Ribavirin - 05/24/04
•	Intron A and Ribavirin for the Treatment Of HCV Patients Who Failed Prior Therapy - 05/19/04
•	Treatment with Pegasys of Non Responders to PEG-Intron: Preliminary 24-week Results - 05/19/04
•	High Dose Consensus Interferon Induction Therapy Results in Successful Retreatment of Peginterferon Nonresponder HCV Patients 05/17/04
•	Interim Results of a Pilot Study of the Combination of Consensus Interferon and Interferon Gamma in HCV Nonresponders to Peginterferon Alfa 2 Plus Ribavirin 05/17/04
•	End of Treatment Response for PEG-IFN + Weight-Based Ribavirin Nonresponders Retreated with Consensus Interferon Plus Ribavirin 05/17/04
•	How Long to Retreat Nonresponders? 05/17/04

Sustained virologic response (SVR)
•	Trend to Improved SVR among African-Americans Receiving High Dose Induction Therapy with Conventional Interferon + Ribavirin - 05/19/04
•	Treatment of Chronic Hepatitis C with Pegasys Plus Ribavirin in Hemophiliac Patients Shows High Rate of Sustained Virologic Response - 05/19/04
•	Switching from PEG-Intron to an Escalating Pegasys Regimen for Recurrent Hepatitis C Post Liver Transplantation May Improve Virological Response and Tolerability 05/17/04
•	Mexican Americans with Chronic HCV Show No Differences in Response to Treatment Compared to Whites 05/17/04
•	Twice a Week Administration of PEG-Intron Plus Ribavirin in Obtaining SVR Among Patients with HCV Genotype 1 05/17/04
•	PEG-Intron Plus Ribavirin for Retreatment of Chronic Hepatitis C 05/17/04

Tests for HCV
•	Oral IDN 6556, an Anti-Apoptotic Caspase Inhibitor, Lowers Aminotransferases in HCV Patients - 05/24/04
•	Simple Noninvasive Index Can Predict Significant Fibrosis in HIV-HCV Coinfected Patients - 05/24/04
•	Treatment with PEG-Intron + Ribavirin Is Effective for Patients with Chronic Hepatitis C and Normal Liver Enzymes - 05/19/04

Retreatment
•	High Dose Consensus Interferon Induction Therapy Results in Successful Retreatment of Peginterferon Nonresponder HCV Patients 05/17/04
•	PEG-Intron Plus Ribavirin for Retreatment of Chronic Hepatitis C 05/17/04
•	How Long to Retreat Nonresponders? 05/17/04

Transplantation
•	Steroid-Free Immunosuppression for Liver Transplantation Recipients with Hepatitis C - 05/21/04
•	Therapy with Peginterferon Alfa Does Not Increase the Risk of Acute Rejection Post Liver Transplantation 05/17/04
•	Switching from PEG-Intron to an Escalating Pegasys Regimen for Recurrent Hepatitis C Post Liver Transplantation May Improve Virological Response and Tolerability 05/17/04
•	Improved Efficacy and Tolerability in Treating Post-Transplant HCV Utilizing an Escalating Regimen of Pegasys and Ribavirin with Hematopoietic Growth Factors 05/17/04

Epidemiology
•	HCV Quasispecies Association with Early Treatment Response in Singly and Coinfected Patients with Inherited Bleeding Disorders - 05/21/04
•	Trend to Improved SVR among African-Americans Receiving High Dose Induction Therapy with Conventional Interferon + Ribavirin - 05/19/04
•	Treatment of Chronic Hepatitis C with Pegasys Plus Ribavirin in Hemophiliac Patients Shows High Rate of Sustained Virologic Response - 05/19/04
•	Mexican Americans with Chronic HCV Show No Differences in Response to Treatment Compared to Whites 05/17/04

Drug adverse events
•	Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV Patients Receiving Interferon/Ribavirin Therapy - 05/24/04
•	Factors That Improve the Efficacy of Epoetin Alfa for Maintenance of Ribavirin Weight-Based Dosing - 05/19/04
•	Darbepoetin Alfa improves Ribavirin-related Anemia and Allows for Maintenance of Optimal Ribavirin Dose 05/17/04

Fibrosis
•	The Long-term Effects of Coinfection with Chronic Hepatitis C and B on Patients with HIV - 05/24/04
•	Viscum Album and Solanum Lycopersicum Inhibit Fibrosis in Chronic Hepatitis C - 05/24/04

Natural History
•	The Long-term Effects of Coinfection with Chronic Hepatitis C and B on Patients with HIV - 05/24/04
•	Impact of Past HBV Infection on the Natural History of Chronic Hepatitis C and Treatment - 05/24/04

Other May News Found on our Web Site

Roche HCV Automated Tests Are Highly Sensitive for Detection of HCV RNA in All Six Hepatitis C Genotypes

Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV

Future Trends of HCV-related Cirrhosis and Hepatocellular Carcinoma in Greece after Adjusting for Access to Peginterferon and Ribavirin

Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial
Liver in Treating Acute Liver Failure

ECCMID: 12-Week Pegylated Interferon Alpha-2b Treatment Effective in Acute Hepatitis C Patients

GENELABS PRESENTS HEPATITIS C VIRUS DRUG DISCOVERY DATA AT INTERNATIONAL CONFERENCE ON ANTIVIRAL RESEARCH

Pastor draws on his faith as he battles hepatitis C

	April 2004 Complementary and Alternative Therapies in the Treatment of Chronic Hepatitis C
	Combination Therapy with Amantadine and Interferon in Treatment-naïve Patients with Chronic Hepatitis C: A Meta-analysis
	Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life
	Doctors suggest monitoring high-risk people for hepatitis C virus
	Senators fail in bid for hep C funding $5.9M to fight disease not in prison budget
	Hepatitis C virus-infected patients and communication with physicians
	Pegasys plus Copegus: Newly Published Data Reports Highest Overall Sustained Virological Response Ever - 63%-All Genotypes Listed
	International Hepatitis C Study to Examine New Approaches to Treat Patients Who Did Not Benefit From Standard Therapy
	Lack of evidence of sexual transmission of Hepatitis C among monogamous couples Selected Non Responders to Prior Interferon-based Therapy Can Achieve a Sustained Virologic Response (SVR) Following Retreatment with Peginterferon Alfa-2a (Pegasys) and Ribavirin
	Selected Highlights from the 39th Annual Meeting of the European Association for the Study of the Liver (39th EASL) April 14 - 18, 2004, Berlin Germany Compiled by Ronald Baker, PhD

	March 2004 Effect of Peginterferon Alfa-2a (Pegasys) on Liver Histology in Chronic Hepatitis C
	Can treating HCV prevent progression to cirrhosis?
	Youths' self-tattooing causes rising concern
	Chiron assailed over its use of hepatitis treatment patents
	Hepatitis Link to Pigs May Hit Transplant Hopes
	A 48-Week Duration of Therapy with Pegylated Interferon alpha 2b plus Ribavirin May Be Too Short to Maximize Long-Term Response among Patients Infected with Genotype-1 Hepatitis C Virus
	Pregnant hepatitis C carriers hold 10% risk of infecting baby
	Treatment according to Genotype:

	Is a 48-week Course of Treatment with Peginterferon Plus Ribavirin Too Short to Maximize a Sustained Viral Response Among Patients with Hepatitis C virus Genotype 1?
	Small Study Finds Positive Results for HCV Non-Responders
	A DGReview of :"Complete or partial seroreversion in immunocompetent individuals after self-limited HCV infection: consequences for transfusion" Transfusion

	Feb 2004 Zadaxin Plus Intron A for Treatment-naive HCV Patients: A Pilot Study
	BILN 2061 Is Effective and Well-Tolerated for HCV Genotype 1 in Preliminary Clinical Trials
	Interferon-Alpha May Be Safe, Effective In Preventing Hepatocellular Carcinoma Recurrence After Ablation Therapy
	Roche's Pegasys for Hepatitis C cure
	Occult infection :No detectable HCV antibodies and no evidence of HCV in serum nevertheless harbor hidden virus elsewhere in the body
	The Severity of Liver Fibrosis Is Associated with High Leptin Levels in Chronic Hepatitis C
	Roche Scientists Identify Small Molecules That Activate A Key Tumor Suppressor Pathway
	HCV Evolves Slowly in Some Patients: Italian researchers conclude from analyzing the virus in a small group of 35 adults who apparently acquired it through blood transfusions at birth.
	Roche Will Announce Study Results
	Results of Re-transplantation for Recurrent Hepatitis C
	HCV Patients with Genotype 1b May Show a Sustained Response and ALT Improvement After Prolonged Re-treatment with Interferon Alfa

	Jan 2004 FDA Approves Pegasys(R) (Peginterferon alfa-2a) Pre-filled Syringes for the Treatment of Hepatitis C
	Coley Pharmaceutical Group Initiates Phase I Clinical Trials of Actilon(TM) for Chronic Hepatitis C Infection
	Chiron Advances Hepatitis C Vaccine Development Program
	Anemia Drug Helpful in Patients with Hepatitis C
	Schering-Plough Announces Availability of REBETOL(R) Oral Solution for Use in Treating Pediatric Hepatitis C

Internet Conference Reports on All New and Current HCV Therapies

2003 Research News and Articles

Selected Highlights from the
39th Annual Meeting of the European Association for the Study of the Liver
(39th EASL)
April 14 - 18, 2004, Berlin Germany
Compiled by Ronald Baker, PhD

HOME	Liver Cancer
FAQ Great Place To Start	Autoimmune Hepatitis
Have You Just Been Diagnosed ?	Other Medical Conditions & HCV
Glossary	HCV Worldwide News & Research
History Of HCV	HCV News Archives 2001-2002
Your Liver Functions	Internet Conference Reports on All New and Current HCV Therapies
Symptoms Of HCV	Nutrition & HCV
Transmission Of HCV	Interviews: Members & Professionals
Sex And HCV	HCV Support Groups Listed By State
Understanding Your Blood Tests Labs	Transplant Support Groups Listed By State
Monitoring Blood Work On Treatment	Insurance, Financial Aid & Free Meds
Liver Biopsy Understanding Your Results	How to Find a Doctor & What to Ask
Viral Loads	Members Share Their First Shot Experience
Genotypes	Shared Stories From Our Members
Infergen	Your Questions & HCV
Inhibitors & New Therapies	Chat Room & Message Boards
Peg Intron & Pegasys	Books On HCV
Help With Side Effects During Treatment	Food For The Soul Inspirational Stories
Drug Interactions & Treatment	Informative Links
Latest HCV Trials	Pictures Of Our Members
Liver Fibrosis	What's New at Janis and Friends
Cirrhosis	Sign Our Guestbook
Transplants	Contact Us mailto:JansDream@angelhaven.com
Current Transplant Research	In Memory Of Janis

Reviewed OCT 03 2004